Results 91 to 100 of about 43,858 (197)

Large‐scale meta‐analysis of infection risk with JAK–STAT inhibitors in 29,000 patients

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this large meta‐analysis of 74 randomized controlled trials involving more than 29,000 patients, JAK–STAT inhibitors were associated with an increased risk of influenza, bronchitis and herpes infections, particularly herpes zoster, while an increased risk of serious opportunistic or fungal infections was not observed.
Máté Krebs, Lili Gulyás, Karen Krisztina Fazekas, Benedek Nagy, Mária Veronika Kolonics, Fanni Adél Meznerics, Norbert Kiss, András Bánvölgyi, Péter Hegyi, Péter Holló, Lajos Vince Kemény   +10 more
wiley   +1 more source

A Real-World Study of Tofacitinib in Indian Patients with Refractory Moderate-to-Severe Atopic Dermatitis, its Economic Considerations and Immunological Rationale

Indian Dermatology Online Journal
Background: The response of atopic dermatitis (AD) to different biologics and JAK inhibitors (JAKibs) is variable due to the varied immunological endotypes of AD.
Kabir Sardana, Savitha Sharath, Sumitra Kumari Meena, Ananta Khurana, Bhawuk Dhir   +4 more
doaj   +1 more source

Antibiotic‐mediated immune modulation in periodontitis

Periodontology 2000, EarlyView.
Abstract Periodontitis is a chronic inflammatory disease affecting the supporting structures of the teeth. Although initiated by dysbiotic microbial communities, its progression is largely driven by the host's uncontrolled inflammatory response. While antibiotics have conventionally been employed in periodontitis therapy for their antimicrobial ...
Lina J. Suárez, R. M. Arce, Camila Pinheiro Furquim, Cristiane Gonçalves, Alpdogan Kantarci, Magda Feres, Nidia C. Castro dos Santos   +6 more
wiley   +1 more source

Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents

American Journal of Hematology, Volume 101, Issue 9, Page 2166-2176, September 2026.
ABSTRACT Hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (alloHSCT) have both demonstrated remissions in VEXAS; however, comparative data is lacking. We conducted a multicenter, retrospective analysis of 66 patients diagnosed with VEXAS syndrome treated with HMA (n = 35) or alloHSCT (n = 31). Baseline characteristics
Saubia Fathima, Margaret Mei‐Kay Wong, Jesus Gonzalez‐Lugo, Susan M. Geyer, Ali Alsugair, Maria Sirenko, Kimberly J. Langer, Terra L. Lasho, Christy Finke, Jun Choi, Maher Abdul‐Hay, Gary Ho, Mark R. Litzow, Aasiya Matin, Urshila Durani, Mehrdad Hefazi, William J. Hogan, Mithun V. Shah, Aref Al‐Kali, Kebede H. Begna, Naseema Gangat, Antoine N. Saliba, Ronald S. Go, Tariq Kewan, Gabriel Bartoo, Jade Kutzke, Kristen McCullough, Kenneth J. Warrington, Megan Sullivan, Kaaren K. Reichard, Horatiu Olteanu, Hemant Murthy, Talha Badar, Yael Kusne, Jeanne Palmer, Saurabh Chhabra, Nathan Punwani, Mary Riwes, Joseph P. McGuirk, Elizabeth F. Krakow, Amelia Langston, Taxiarchis Kourelis, David Dingli, James Foran, Matthew J. Koster, Mrinal M. Patnaik, David B. Beck, Hassan B. Alkhateeb, Abhishek A. Mangaonkar   +48 more
wiley   +1 more source

Comparative Effectiveness Analysis of Phase 3 Clinical Trials in Moderately to Severely Active Inflammatory Bowel Disease Reveals Increased Harm From Placebo and Challenges Equipoise

JCC Plus, Volume 1, Issue 5, September 2026.
Across 47 Phase 3 trials in Crohn's disease and ulcerative colitis, placebo exposure was associated with measurable harm. Disease exacerbation events showed the greatest excess risk, with one additional exacerbation occurring for every 8–13 patients assigned to placebo rather than active therapy.
Joëlle St‐Pierre, Zachary D. Fine, Evan N. Fear, Jeremy A. Klein, Natalie K. Choi, David T. Rubin   +5 more
wiley   +1 more source

Successful Management of Persistent DRESS with Tofacitinib: Two Case Reports

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Marc Hernández‐Santacana, Ignasi Martí‐Martí, Victoria Amat‐Samaranch, Irene Fuertes de Vega, Priscila Giavedoni, José M. Mascaró Jr   +5 more
wiley   +1 more source

Hepatitis E Infection in Patients With IBD Treated With Advanced Therapy: A Case Series

JCC Plus, Volume 1, Issue 5, September 2026.
ABSTRACT Background and Aims Hepatitis E virus is an RNA virus with 8 genotypes. Infection is usually acute and asymptomatic, but chronic infection may develop in immunocompromised individuals. Data on the course of hepatitis E virus infection in patients with inflammatory bowel disease receiving advanced therapy are limited.
Jakub Jirsa, Kristyna Kubickova, Dana Duricova   +2 more
wiley   +1 more source

Characterization of a Large Hispanic Cohort With Inflammatory Bowel Disease Across a 26‐Year Span: The University of Puerto Rico Registry

JCC Plus, Volume 1, Issue 5, September 2026.
ABSTRACT Background and Aims The limited data on ethnic minorities with inflammatory bowel disease (IBD) is a growing concern, given its increasing incidence in Hispanics in the United States and Latin America. Our aim was to describe a large cohort of Hispanics with IBD studied over two decades.
Alondra Soto‐González, Lizzie M. Ramos‐Tollinchi, Claudia Amaya‐Ardila, Paola López‐Marte, Andrea Sánchez‐Velázquez, Karla Feliciano‐Salva, María T. Anca‐Fullana, Patricia Figueroa‐Rodríguez, Esther A. Torres   +8 more
wiley   +1 more source

Inflammatory Bowel Disease: Mechanisms and Therapeutic Advances

MedComm, Volume 7, Issue 9, September 2026.
Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's disease, is a rising, multifactorial chronic disorder driven by dysregulated mucosal immunity in genetically susceptible individuals and influenced by environmental and microbial factors.
Andrea Papait, Anna Cargnoni, Franco Scaldaferri, Loris Lopetuso, Antonietta Rosa Silini, Ornella Parolini   +5 more
wiley   +1 more source

Incidence of Hepatitis B Virus Reactivation in Patients Treated With Immunosuppressive and Chemotherapeutic Agents

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 5, Page 625-634, September 2026.
HBV reactivation incidence varied across immunosuppressive and chemotherapeutic agents. Clinically meaningful HBV reactivation was also observed in patients receiving corticosteroids and conventional immunosuppressive therapies. ABSTRACT Background Data on the incidence of hepatitis B virus reactivation (HBVr) remain limited. In Japan, patients who are
Kazuhiko Ikeuchi, Makoto Saito, Kazuya Okushin, Toshiyuki Kishida, Akira Kado, Kyoji Moriya, Kazuhiko Koike, Takeya Tsutsumi, Hiroshi Yotsuyanagi   +8 more
wiley   +1 more source